Hiromi Nyuzuki

Dr. Hiromi Nyuzuki


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Keisuke NagasakiKeisuke Nagasaki
Keisuke Nagasaki
HSHidetoshi Sato
Hidetoshi Sato
SSSunao Sasaki
Sunao Sasaki
HNHiromi Nyuzuki
Hiromi Nyuzuki
NSNao Shibata
Nao Shibata
TATadashi Asami
Tadashi Asami
Although newborn screening (NBS) for congenital hypothyroidism (CH) in Japan started more than 40 years ago, the prevalence of CH remains unclear. Prevalence estimations among NBS-positive CH individuals include those with transient hypothyroidism and transient hyperthyrotropinemia, and re-evaluation with increasing age is necessary to clarify the actual incidence. Thus, we re-evaluated the incidence of permanent CH. Of the 106,114 patients who underwent NBS in the Niigata Prefecture, Japan, between April 2002 and March 2006, 116 were examined further due to high thyroid-stimulating hormone levels (>8 mIU/L) and were included in the study. We retrospectively evaluated their levothyroxine sodium (LT4) replacement therapy status from the first visit to 15 years of age. Of the 116 NBS-positive patients, 105 (91%) were initially examined in our department. Of these, 72 (69%) started LT4 replacement therapy on the first visit. Subsequently, 27 patients continued LT4 replacement until 15 years of age after multiple re-evaluations. The prevalence of permanent CH in the Niigata Prefecture during this period was 1 in 2500–3500 children. Ultimately, 62.5% of patients on LT4 replacement discontinued treatment by 15 years of age. This is the first study to clarify the true prevalence of permanent CH in Japan.

15 December 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KKKazuki Kodera
Kazuki Kodera
RHRyuichi Hishida
Ryuichi Hishida
ASAkiko Sakai
Akiko Sakai
HNHiromi Nyuzuki
Hiromi Nyuzuki
NMNoriko Matsui
Noriko Matsui
Hideaki MatsuiHideaki Matsui
Hideaki Matsui

22 February 2024 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
HNHiromi Nyuzuki
Hiromi Nyuzuki
JOJunichi Ozawa
Junichi Ozawa
Keisuke NagasakiKeisuke Nagasaki
Keisuke Nagasaki
YNYosuke Nishio
Yosuke Nishio
TOTomoo Ogi
Tomoo Ogi
TITakeshi Ikeuchi
Takeshi Ikeuchi
Cardiospondylocarpofacial syndrome (CSCFS) is a congenital malformation characterized by growth retardation, facial features, short toes with carpal and tarsal fusion, extensive posterior neck vertebral fusion, congenital heart disease, and deafness. Here, we report a severe case of CSCFS with a novel variant, p.Thr187Ile, in MAP3K7. Thr187 is the main phosphorylation site for TGF-beta-activated kinase 1 encoded by MAP3K7, and this variant may cause significant abnormalities in downstream signaling.

3 August 2023 in Children
Verified
Journal Article
Open access
PDF file
TOTakanori Onuki
Takanori Onuki
SHShota Hiroshima
Shota Hiroshima
KSKentaro Sawano
Kentaro Sawano
NSNao Shibata
Nao Shibata
YOYohei Ogawa
Yohei Ogawa
HNHiromi Nyuzuki
Hiromi Nyuzuki
Background: There are reports of mothers being diagnosed with inborn errors of metabolism (IEM) via positive newborn screening (NBS) of their newborns. Mothers with IEM are often considered to have mild cases of little pathological significance. Based in Niigata Prefecture, this study aimed to investigate mothers newly diagnosed with IEM via positive NBS in their newborns using tandem mass spectrometry, and to clarify the disease frequency and severity. Methods: This was a single-institution, population-based, retrospective study. The subjects were mothers whose newborns had false-positive NBS, among 80,410 newborns who underwent NBS between April 2016 and May 2021. Result: there were 3 new mothers were diagnosed with IEM (2 with primary systemic carnitine deficiency (PCD) and 1 with 3-methylcrotonyl-CoA carboxylase deficiency) out of 5 who underwent examination among 18 false positives. The opportunity for diagnosis was low C0 and high C5-OH acylcarnitine levels in their newborn. Two novel SLC22A5 variants (c.1063T > C/c.1266A > G) were identified in patients with PCD. None of the patients had any complications at the time of diagnosis, but two patients showed improvement in fatigue and headache after taking oral carnitine. Conclusion: New mothers with IEM cannot be considered as mild cases and need to be treated when necessary. The two novel SLC22A5 variants further expand the variant spectrum of PCD.

23 October 2025 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
MHMizuki Harada
Mizuki Harada
TOTakanori Onuki
Takanori Onuki
HNHiromi Nyuzuki
Hiromi Nyuzuki
HSHisato Suzuki
Hisato Suzuki
KIKozue Ito
Kozue Ito
HSHiroshi Suzuki
Hiroshi Suzuki
Here we report a de novo heterozygous MED13 variant (c.2503C>T, p.Pro835Ser) in an infant presenting with infantile spasms, hypertrophic cardiomyopathy and hepatomegaly. Autopsy revealed mitochondrial abnormalities in cardiac and hepatic tissues, with reduced respiratory chain complex activity. This is the first case report linking a MED13 variant to systemic mitochondrial dysfunction, suggesting a novel pathogenic mechanism.

4 December 2024 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
MHMoemi Hojo
Moemi Hojo
NSNoriko Soma
Noriko Soma
KYKei Yamada
Kei Yamada
YKYu Kobayashi
Yu Kobayashi
MMMasaki Miura
Masaki Miura
JTJun Tohyama
Jun Tohyama
Bryant-Li-Bhoj syndrome (BLBS; OMIM # 619720, 619721), caused by germline H3F3A and H3F3B variants encoding histone H3.3, is characterized by mild to severe developmental delay, intellectual disability, failure to thrive, muscle tone abnormalities, and dysmorphic facial features. Here, we present a Japanese patient with a novel heterozygous p.A48G variant in H3F3A, displaying previously unrecognized symptoms of neonatal myoclonus. This case helps broaden the phenotypic spectrum of BLBS.